Immunogenicity Assessment for the Successful Development of Biosimilars

Posted by

SELECTBIO

Michael Tovey, Director, Institut Andre Lwoff

Abstract
Successful development of biosimilars requires the establishment of a validated and standardized assay that allows direct comparisons of the relative potency and immunogenicity of innovator molecules and biosimilars as illustrated by case studies for interferon beta products and TNF-alpha antagonists.